135 results
8-K
EX-10.1
KPTI
Karyopharm Therapeutics Inc
14 May 24
Other Events
4:06pm
) in connection with any actual or alleged damage, injury, threat or harm to health, safety, natural resources or the environment.
“Environmental … ; or (iii) occupational safety and health, industrial hygiene, land use or the protection of human, plant or animal health or welfare (with respect
8-K
EX-4.1
KPTI
Karyopharm Therapeutics Inc
14 May 24
Other Events
4:06pm
a sufficient number of subjects and is designed to establish that such product has an acceptable safety and efficacy profile for its intended use
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
8 May 24
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
7:47am
), evaluating the efficacy and safety of selinexor monotherapy at 60 mg QW or 40 mg QW in subjects (n=58) with JAK inhibitor-naïve myelofibrosis … benefit in confirmatory trial(s).
Targeting Disease at the Nuclear Pore
SELECT IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Thrombocytopenia
8-K
EX-99.1
w0alwo fwcydq
29 Feb 24
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
7:35am
8-K
EX-99.1
roai6s02ee58nekpza
8 Jan 24
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
8:40am
8-K
EX-99.1
3r3p6aybm9v vbk
2 Nov 23
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
7:37am
8-K
EX-99.1
s13qb
2 Aug 23
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
7:37am
8-K
EX-99.1
e2w0ljegxc4zy
4 May 23
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
7:53am
8-K
cee362jp
13 Dec 22
Other Events
5:36pm
8-K
EX-10.1
0bp k0xrdd31i
5 Dec 22
Karyopharm Announces $165 Million Private Placement
8:41am
8-K
EX-3.1
8b6v 2cgif5s6urd
2 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:05pm